VWAP

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Retrieved on: 
Monday, March 11, 2024

DOYLESTOWN, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has entered into a securities purchase agreement with new and existing healthcare focused institutional investors and certain Company insiders to raise up to $34.0 million in gross proceeds, including initial upfront funding of $16.0 million and up to an additional $18.0 million upon cash exercise of accompanying warrants at the election of the investors.

Key Points: 
  • “This meaningful financing led by high quality healthcare institutions will support Aprea in our goal to be a leader in the field of Synthetic Lethality (SL) and DNA Damage and Response (DDR),” said Dr. Oren Gilad, President and CEO of Aprea.
  • The private placement is expected to close on or about March 13, 2024 subject to satisfaction of customary closing conditions.
  • Aprea intends to use the upfront net proceeds from the private placement for general corporate purposes and to fund clinical development of APR-1051, the Company’s WEE1 inhibitor product candidate which recently received IND clearance.
  • Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Retrieved on: 
Monday, March 11, 2024

The Convertible Notes will be senior, secured obligations of Dyadic and its affiliates, and interest will be payable quarterly in cash on the principal amount equal to 8% per annum.

Key Points: 
  • The Convertible Notes will be senior, secured obligations of Dyadic and its affiliates, and interest will be payable quarterly in cash on the principal amount equal to 8% per annum.
  • The Convertible Notes will mature on March 8, 2027 (the “Maturity Date”), unless earlier converted, repurchased, or redeemed in accordance with the terms of the Convertible Notes.
  • The Convertible Notes will be convertible into shares of Dyadic’s Class A common stock (the “Common Stock”), at the option of the holders of the Convertible Notes (the “Noteholders”) at any time prior to the Maturity Date.
  • “I would like to extend our gratitude to long-term shareholders for their steadfast support.

IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences

Retrieved on: 
Monday, March 11, 2024

Concurrently to entering into the Loan Agreement, the Company has issued 4,000,000 warrants (the “Warrants”) to atai.

Key Points: 
  • Concurrently to entering into the Loan Agreement, the Company has issued 4,000,000 warrants (the “Warrants”) to atai.
  • The Warrants entitle atai to purchase Shares at a price of US$0.17 per Share, for a period of 36 months following their issuance.
  • The shorter period was necessary in order to permit the Company to close the Loan Agreement in a timeframe consistent with usual market practice for transactions of this nature.
  • This press release does not constitute an offer of securities for sale in the United States.

Aussie Vapes Granted Import License in Australia  

Retrieved on: 
Friday, March 8, 2024

“As a leading Australian online supplier of aromatherapy products, being granted this TGA import license improves our competitive advantage even further,” said Meni Morim, CEO of Lifeist.

Key Points: 
  • “As a leading Australian online supplier of aromatherapy products, being granted this TGA import license improves our competitive advantage even further,” said Meni Morim, CEO of Lifeist.
  • Aussie Vapes has an important role to play, and we wholeheartedly support the TGA's initiatives to reduce nicotine product misuse by minors.
  • As an established market leader in Australia, Aussie Vapes recognizes that navigating the aromatherapy vaporizer import license application process presents a complicated challenge for smaller participants in the space.
  • As the new market landscape for these devices continues to evolve in Australia, Aussie Vapes will take a leading role in exploring ways to use our import license to help support smaller retailers in a fully regulatorily compliant and transparent fashion.

Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results

Retrieved on: 
Tuesday, March 5, 2024

Additionally, the Company announces that it will report its Preliminary Results for the twelve months ended 31 December 2023 on Monday 29 April 2024.

Key Points: 
  • Additionally, the Company announces that it will report its Preliminary Results for the twelve months ended 31 December 2023 on Monday 29 April 2024.
  • In line with guidance provided at the Interim Results, revenues for the year ended 31 December 2023 are expected to be approximately £90 million.
  • Operating EBITDA loss for the second half of 2023 is on track to be approximately £10 million better than the first half, as previously guided.
  • A briefing for investors and analysts will take place at 13:00 BST / 08:00 ET at One Moorgate Place, London, EC2R 6EA.

Puma Announces a Creative Deal to Unlock Value of its Assets in New Brunswick

Retrieved on: 
Monday, March 4, 2024

Before the execution of the Raptor Agreements, Puma was holding a 100% interest in each of the Projects.

Key Points: 
  • Before the execution of the Raptor Agreements, Puma was holding a 100% interest in each of the Projects.
  • The sale of the Chester and Turgeon Projects to Raptor will allow Puma to further monetize its copper assets and unlock their value.
  • We’re always looking to increase shareholder value and creative ways to finance and control share dilution.
  • The objective for Puma is to receive from Raptor the same consideration value as the one that it negotiated in its initial option deal with Canadian Copper, of which CAD $2M remains receivable.

First Advantage to Acquire Sterling Check Corp. for $2.2 Billion in Cash and Stock

Retrieved on: 
Thursday, February 29, 2024

First Advantage will issue a combination of cash and stock valuing Sterling at approximately $2.2 billion, including Sterling’s outstanding debt.

Key Points: 
  • First Advantage will issue a combination of cash and stock valuing Sterling at approximately $2.2 billion, including Sterling’s outstanding debt.
  • First Advantage will share additional forward-looking financial information regarding the transaction’s impact at or around the time of closing.
  • The transaction consideration is comprised of approximately $1.2 billion in cash and 27.15 million shares of First Advantage common stock.
  • Under the terms of the agreement, Sterling shareholders will elect to receive either $16.73 in cash or 0.979 shares of First Advantage common stock for each Sterling share.

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Retrieved on: 
Wednesday, February 28, 2024

Additional information regarding the composition of the Board is available in a Current Report on Form 8-K filed with the SEC.

Key Points: 
  • Additional information regarding the composition of the Board is available in a Current Report on Form 8-K filed with the SEC.
  • vTv expects to use the proceeds from the PIPE to fund the first Phase 3 study of its lead product candidate, cadisegliatin, which is expected to initiate in mid-2024.
  • JDRF is the world’s largest nonprofit funder of T1D research focused on accelerating cures, preventing, and treating T1D.
  • There are more than 18 million people living with T1D worldwide with fewer than 30% meeting their A1c targets, demonstrating the clear need for additional therapies.

Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal Trial

Retrieved on: 
Wednesday, February 28, 2024

“The additional cash runway and the overall reduction in cash needs gives us the flexibility to advance our core asset and continue partnering and strategic discussions.

Key Points: 
  • “The additional cash runway and the overall reduction in cash needs gives us the flexibility to advance our core asset and continue partnering and strategic discussions.
  • Specifically, this provides an opportunity to deliver on the promise of NCX 470 in glaucoma, and thereby to preserve and create value.
  • Under the current bond agreement, Nicox was due to begin repaying the Amortizing Bond to Kreos from 1 February 2024.
  • The debt restructuring and cost reductions extend the Company’s cash runway to November 2024, based on focusing exclusively on the development of NCX 470.

American Rare Earths Announces A$13.5m Placement to advance Halleck Creek Project

Retrieved on: 
Thursday, February 22, 2024

DENVER, Feb. 22, 2024 (GLOBE NEWSWIRE) -- American Rare Earths Limited (ASX: ARR | ADRs – OTCQX: AMRRY | Common Shares – OTCQB: ARRNF) (“ARR” or the “Company”) is pleased to announce that it has received firm commitments for a placement of 45 million new fully paid ordinary shares (“New Shares”) at an issue price of A$0.30 to raise A$13.5 million (“Placement”).

Key Points: 
  • The overwhelming support from both existing shareholders and new institutional investors underscores the confidence in our vision and the potential of our projects in particular the Halleck Creek Rare Earth Project.
  • This Placement provides us with the capital to advance our flagship project, Halleck Creek, towards delivering a secure supply of critical minerals to the North American supply chain.
  • Proceeds from the Placement, together with existing cash, will be used to fund the continued development of the Company’s flagship Halleck Creek Rare Earths Project in Wyoming, USA.
  • This market announcement has been authorized for release by the Chairman of American Rare Earths Limited.